← Frontiers in Hematology

Papers in Frontiers in Hematology

Page 2 · newest first

51. Case report: Clinical characteristics and genetic analysis of a familial platelet disorder associated with RUNX1 gene mutationFrontiers in Hematology · 2025
52. Understanding therapy-related AML: genetic insights and emerging strategies for high-risk patientsFrontiers in Hematology · 2025
53. Successful management of acute promyelocytic leukemia in the third trimester of pregnancy: a case report and review of the literatureFrontiers in Hematology · 2025
54. Downregulated PTEN and aberrant JAK–STAT signal pathway in essential thrombocythemia patientsFrontiers in Hematology · 2025
55. Trends in hemolytic anemia-related mortality in the United States from 1999-2022Frontiers in Hematology · 2025
56. Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndromeFrontiers in Hematology · 2025
57. Not just for mature audiences: myeloproliferative neoplasms in children, adolescents, and young adultsFrontiers in Hematology · 2025
58. Erythroblast island macrophages and their surface markersFrontiers in Hematology · 2025
59. Disease and treatment burden in patients with leukaemia: family members/partner perspectiveFrontiers in Hematology · 2025
60. Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutationsFrontiers in Hematology · 2025
61. Metabolic reprogramming of fetal hematopoietic stem and progenitor cells by maternal obesityFrontiers in Hematology · 2025
62. Anemia and its predictors among neonates at Wachemo University teaching hospital, Central Ethiopia: a facility-based cross-sectional studyFrontiers in Hematology · 2025
63. Assessing maternal and perinatal complication incidence in pregnant patients with sickle cell disease: a retrospective analysis of transfusion therapy at a tertiary care hospitalFrontiers in Hematology · 2025
64. Cochrane’s contribution to global health: three decades of progress in sickle cell disease researchFrontiers in Hematology · 2025
65. Exercise and diet studies among patients living with multiple myeloma: current evidence and considerations of patient preferencesFrontiers in Hematology · 2025
66. Editorial: Hematopoietic stress in stem cell homeostasis and disease pathogenesisFrontiers in Hematology · 2025
67. Case Report: Triplet combination with pirtobrutinib/venetoclax/rituximab in accelerated phase of chronic lymphocytic leukemiaFrontiers in Hematology · 2025
68. Abnormalities of primary and secondary hemostasis in multiple myeloma: insights from studies on thrombopoiesis, the coagulation system, and the bone marrow microenvironmentFrontiers in Hematology · 2025
69. FACIT-Fatigue scale in patients with cold agglutinin disease: psychometric validation and estimation of clinically meaningful changeFrontiers in Hematology · 2025
70. The role of glucocorticoids in erythropoiesisFrontiers in Hematology · 2025
71. Acquired von Willebrand disease associated with smoldering multiple myeloma and hereditary hemorrhagic telangiectasia successfully treated with daratumumab, pomalidomide, and dexamethasone: hitting three birds with one stone? – case reportFrontiers in Hematology · 2025
72. Time to initiation of antiresorptive agents in multiple myeloma to reduce skeletal related eventsFrontiers in Hematology · 2025
73. The aging hematopoietic stem cell niche: a mini reviewFrontiers in Hematology · 2025
74. Editorial: Two decades of targeted therapies in hematology: new targets and novel combinationsFrontiers in Hematology · 2025
75. Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional studyFrontiers in Hematology · 2025
76. Case report: VEXAS syndrome: first documented cases in Latin AmericaFrontiers in Hematology · 2025
77. Unique target binding by the C-terminal region of FHR1 provides a new perception of aHUS pathologyFrontiers in Hematology · 2024
78. Leveraging big data and artificial intelligence for smarter trials in myeloproliferative neoplasmsFrontiers in Hematology · 2024
79. A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case reportFrontiers in Hematology · 2024
80. Ruxolitinib and pegylated interferon in Chronic Neutrophilic Leukemia due to a pathogenic CSF3R germline variant: a case reportFrontiers in Hematology · 2024
81. Case report: Vitamin B12 deficiency-associated hemolytic anemiaFrontiers in Hematology · 2024
82. Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)Frontiers in Hematology · 2024
83. Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric studyFrontiers in Hematology · 2024
84. Delineation of erythropoietic intermediates by flow cytometryFrontiers in Hematology · 2024
85. Rare cell-based liquid biopsy for improved measurement of low-grade chronic inflammationFrontiers in Hematology · 2024
86. Exploring the regenerative capacity of the spleen following irradiationFrontiers in Hematology · 2024
87. Distinct clinico-genomic factors drive outcomes in patients with myelofibrosis and disease-related anemiaFrontiers in Hematology · 2024
88. Late onset pancytopenia post chimeric antigen receptor T cell therapy triggered by a COVID-19 vaccination: a case reportFrontiers in Hematology · 2024
89. Case report: VEXAS syndrome and literature reviewFrontiers in Hematology · 2024
90. Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoringFrontiers in Hematology · 2024
91. The CHIP-clinic as the catalyst of preventive medicineFrontiers in Hematology · 2024
92. Clonal evolution: a landmark of MPN evolutionFrontiers in Hematology · 2024
93. Recent advancements in gene therapy for sickle cell disease and β-thalassemiaFrontiers in Hematology · 2024
94. Dissecting dormancy and quiescence in hematopoietic stem cellsFrontiers in Hematology · 2024
95. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantationFrontiers in Hematology · 2024
96. Sickle cell disease: a comparative perspective on global and national initiativesFrontiers in Hematology · 2024
97. Editorial: Glycobiology in hematology: a promising avenue for cancer diagnostics and therapeuticsFrontiers in Hematology · 2024
98. The nexus between Helicobacter pylori infection and anemia—a systematic reviewFrontiers in Hematology · 2024
99. Are we ready to integrate 3D culture systems in acute myeloid leukemia and bone marrow microenvironment research?Frontiers in Hematology · 2024
100. Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life studyFrontiers in Hematology · 2024